Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Revance Therapeutics (RVNC) Misses Q1 EPS by 7c; Offers FY23 Revenue Guidance
May 9, 2023 4:58 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.74), $0.07 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $49.3 million versus the consensus estimate of $45.73 million.
GUIDANCE:
Revance Therapeutics sees FY2023 revenue of $460-480 million.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
... More